Advertisement

A Therapeutic Trial of a Thymic Factor in Amyotrophic Lateral Sclerosis (ALS)

  • L. Provinciali
  • A. R. Giovagnoli
  • P. Di Bella
  • M. Baroni
  • R. Dellantonio
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 209)

Abstract

Previous studies supported the hypothesis that some immunological abnormalities might be involved in the pathogenesis of ALS. On this basis some therapeutic trials have been attempted with various immunomodulating agents such as isoprinosine[1,2] levamisole[3], transfer factor[4] and interferon[5]. Other therapeutic trials, which have been based on the assumption that ALS may be considered an autoimmune disease, have used immunosuppressor drugs such as azathiopurine, methotrexate and cytotosine-arabinoside[6]. No significant results were described in any of these studies.

Keywords

Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis Patient Therapeutic Trial Transfer Factor Motor Neuron Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    G. Fareed and H. R. Tyler, The use of isoprinosine in ALS, Neurology, 21: 937–940 (1971).PubMedCrossRefGoogle Scholar
  2. 2.
    J. A. Brody, K. M. Chen, Y. Yase, E. M. Holden, and C. E. Morris, Inosiplex and amyotrophic lateral sclerosis, Arch.Neurol., 30: 322–323 (1974).PubMedCrossRefGoogle Scholar
  3. 3.
    M. R. Olarte, Therapeutic trials in amyotrophic lateral sclerosis, in: “Human Motor Neuron Diseases,” L. P. Rowland, ed., Raven Press, New York, pp. 555–567 (1982).Google Scholar
  4. 4.
    M. R. Olarte, J. C. Gersten, J. Zabriskie, and L. Rowland, Transfer factor is ineffective in amyotrophic lateral sclerosis, Ann.Neurol., 5: 385–388 (1978).CrossRefGoogle Scholar
  5. 5.
    A. Rissanen, J. Palo, C. Myllyla, and K. Cantell, Interferon therapy for ALS, Ann.Neurol., 7: 392 (1980).PubMedCrossRefGoogle Scholar
  6. 6.
    F. H. Norris, The riddle of positive immune system findings in amyotrophic lateral sclerosis, in: “Clinical Neuroimmunology,” Clifford Rose, ed., Blackwell Scientific Publications, pp. 245–258 (1979).Google Scholar
  7. 7.
    P. O. Behan, H. M. Dick, and W. F. Durward, Histocompatibility antigens associated with motor neuron diseases, J.Neurol.Sci., 32: 213–217 (1979).CrossRefGoogle Scholar
  8. 8.
    P. H. Hoffman, D. S. Robbins, M. T. Nolte, C. J. Gibbs, and D. C. Gajdusek, Cellular immunity in amyotrophic lateral sclerosis and Parkinsonism-dementia, N.Eng.J.Med., 299: 680–685 (1978).CrossRefGoogle Scholar
  9. 9.
    J. P. Antel, Immunology of amyotrophic lateral sclerosis, in: “Human Motor Neuron Diseases,” L. P. Rowland, eds., Raven Press, New York, pp. 395–402 (1982).Google Scholar
  10. 10.
    P. C. Doherty, Cell-mediated immunity and the CNS: a key role for gamma interferon, T.I.N.S., 11: 41–42 (1985).Google Scholar
  11. 11.
    T. L. K. Low, G. B. Thurman, C. Chincarini, J. E. McClure, G. D. Marshall, S. Hu, and A. L. Goldstein, Current status of thymosin research: evidence for the existence of a family of thymic factors that control T-cell maturation, Ann.N.Y.Acad.Sci., 332: 33–48 (1979).PubMedCrossRefGoogle Scholar
  12. 12.
    A. Goldstein, G. B. Thurman, G. Cohen, and J. Hooper, Thymosin: Chemistry, biology and clinical applications, in: “Biological Activity of Thymic Hormone,” D. Von Bekkum, ed., Kooyer Sci.Pubi., Rotterdam (1974).Google Scholar
  13. 13.
    D. W. Wara, A. L. Goldstein, N. E. Doyle, and A. J. Ammann, Thymosin activity in patients with cellular immunodeficiency, N.Engl.J.Med., 292: 70–75 (1975).PubMedCrossRefGoogle Scholar
  14. 14.
    P. A. Tovo and P. Nicola, TP1 Therapy in patients with secondary immunodeficiencies, in: “Thymus, Thymic Hormones and T Lymphocytes,” Aiuti and Wigzell, eds., Academic Press, London (1980).Google Scholar
  15. 15.
    L. Businco, Therapy with Tpl of viral diseases in immunodeficient patients, in: “Thymus, Thymic Hormones and T Lymphocytes,” Aiuti and Wigzell, eds., Academic Press, London (1980).Google Scholar
  16. 16.
    P. Nicola, Effetti della terapia con TP1 in due pazienti conencefalite morbillosa, Immunol.Pediatr., IX: 40 (1980).Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • L. Provinciali
    • 1
  • A. R. Giovagnoli
    • 1
  • P. Di Bella
    • 1
  • M. Baroni
    • 1
  • R. Dellantonio
    • 1
  1. 1.Instituto delle Malattie del Sistema NervosoUniversity of AnconaItaly

Personalised recommendations